News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Bishal Gyawali: A pseudo-innovation for which you get to pay more without any added benefits
Photo of Bishal Gyawali taken from qcri.queensu.ca
Feb 14, 2024, 19:39

Bishal Gyawali: A pseudo-innovation for which you get to pay more without any added benefits

Bishal Gyawali, Associate Professor and Medical Oncologist at 

“Read the news that NALIRIFOX got approved today by the FDA. Don’t be misled to believe that this represents any innovation. This is a pseudo-innovation for which you get to pay more without any added benefits. We discuss this and other pancreatic cancer treatments in our recent The Lancet Oncology essay.”

Proceed to the essay.
Source: Bishal Gyawali/X

Bishal Gyawali cancer FDA NALIRIFOX OncoDaily Oncology Pancreatic Cancer pancreatic cancer treatment Queen’s University The Lancet Oncology
Special Coverage
Insight
Oct 9, 2024, 12:36
Myeloma Paper of the Day, October 9th, suggested by Robert Orlowski
Blog
Oct 9, 2024, 12:28
MD Anderson Cancer Center and UICC collaborate to improve women's cancer care
Dialogues
Oct 9, 2024, 12:18
ASCO24 Updates: Dr. Daniel McFarland on Patient Portals and Oncology Communication
Blog
Oct 9, 2024, 12:05
Janet Woodcock has joined the Board of Directors of Every Cure
Blog
Oct 9, 2024, 12:04
Dana-Farber/Boston Children's ranked among the best pediatric cancer programs in the nation for 18th year in a row
Blog
Oct 9, 2024, 11:52
Addressing cancer disparities and inequalities for people with HIV - NCI Division of Cancer Control and Population Sciences
Blog
Oct 9, 2024, 11:49
The call for applications is open for the NIH/PEPFAR Local Implementation Science Network - NCI Center for Global Health
Blog
Oct 9, 2024, 11:42
Francisco J. Esteva: Rising breast cancer rates and disparities among women under 50
Insight
Oct 9, 2024, 11:40
Datopotamab Deruxtecan Trial Shows Negative OS in TROPION-Lung 01 - Panot Sainamthip
Blog
Oct 9, 2024, 11:35
Amol Akhade: The Tyranny of Non-Inferiority Trials
Blog
Oct 9, 2024, 11:30
Scientific publication on bias assessment in epidemiological studies - IARC
Blog
Oct 9, 2024, 11:08
Stereotactic Ablative Radiation trial results published in Red Journal - ESTRO